Camlin Fine Sciences Limited

BSE: 532834 NSE: CAMLINFINE
Camlin Fine Sciences Limited - chemicals and materials in Mumbai, Maharashtra, India. FY 2026 financials & compliance.
CIN L74100MH1993PLC075361 Incorporated 30 November 1993 ROC Mumbai HQ Mumbai, Maharashtra, India
Active Listed - NSE: CAMLINFINE · BSE: 532834 Public Limited Company chemicals and materials
Data last updated
Market Cap
₹1,868 Cr
CAMLINFINE · NSE
Share Price
₹97.30
+0.05% today
Revenue
₹1,723 Cr
FY 2025-26 · -0.2% YoY
EBITDA
₹91.39 Cr
Margin 5.3%
Net Profit
₹36.46 Cr
FY 2025-26 · +9998.0% YoY
P/E (TTM)
0.0x
P/B 1.8x
ROE
3.3%
ROCE 4.7%
Debt / Equity
0.71
Interest cover 404.9x

About Camlin Fine Sciences Limited

Data last updated: 26 September 2026

Camlin Fine Sciences Limited is a public limited company based in Mumbai, Maharashtra, India. It specialises in specialty chemicals, a part of the broader chemicals and materials sector. Incorporated on 30 November 1993, the company has been in operation for over 33 years.

Registered with ROC Mumbai under CIN L74100MH1993PLC075361. Listed on BSE: 532834 and NSE: CAMLINFINE.

Capital: an authorised share capital of ₹25 Cr and a paid-up capital of ₹19.21 Cr. Formerly known as Camlicon Consultants Private Limited and Camlin Fine Chemicals Private Limited. It is led by directors including Ashish Subhash Dandekar and Nirmal Vinod Momaya.

Last AGM: 08 August 2025. Financial statements filed for year ended 31 March 2025. Office: Mumbai, Maharashtra.

As per the latest consolidated financials for FY 2025-26, the company reported a revenue of ₹1,723.31 Cr, a growth of 5.81% compared to the previous year. The net worth stands at ₹1,040.88 Cr (up 15.44% YoY). Total assets are valued at ₹1,728.66 Cr (up 12.79% YoY).

The company has a workforce of approximately 612 employees as per the latest available data. Its group structure includes 2 subsidiaries.

The company is associated with 1 brand - Camlin Fine Sciences. As per MCA filings, the company has open charges of ₹636.6 Cr and satisfied charges of ₹1,187.59 Cr on record.

The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website camlinfs.com.

Company Details of Camlin Fine Sciences Limited
CIN L74100MH1993PLC075361
Registration Number 075361
Incorporation Date 30 November 1993
ROC Mumbai
Listing Status Listed (BSE: 532834, NSE: CAMLINFINE)
Company Status Active
Date of Last AGM 08 August 2025
Date of Balance Sheet 31 March 2025
Compliance Status Active Compliant
Key People
Ashish Subhash Dandekar Managing Director Nirmal Vinod Momaya Managing Director Arjun Sudhakar Dukane Whole-Time Director
Contact Details
  • Email
    Locked
  • Telephone
    Locked
  • Website
    camlinfs.com
  • Social Media
  • Registered Address
    In G.S. Point Plot No. Viii C.S.T. Road Private Layout Scheme Kalina Santacruz, East, Mumbai, Maharashtra, India – 400098
  • Industry
    Chemicals and Materials, Specialty Chemicals
Company report
Camlin Fine Sciences Limited - full intelligence report
  • Historical Financials and ratios
  • Shareholding pattern and group structure
  • Charges with holder and property details
  • Litigation, compliance and MCA filings
  • PDF report delivered after checkout
₹799 ₹999 20% off
Secure checkout · GST invoice included

Unlock the full Camlin Fine Sciences Limited report

Financials, compliance, directors, charges, ownership and filings for Camlin Fine Sciences Limited in one report.

10-year financials Directors & ownership Charges & compliance

Name History of Camlin Fine Sciences Limited

Camlin Fine Sciences Limited has undergone 3 name changes throughout its history. The company was previously known as Camlicon Consultants Private Limited, Camlin Fine Chemicals Private Limited, and Camlin Fine Chemicals Limited. The current legal name is Camlin Fine Sciences Limited, reflecting the company's evolution and rebranding over time.

Company Name Status
Camlin Fine Sciences Limited Current
Camlicon Consultants Private Limited Previous
Camlin Fine Chemicals Private Limited Previous
Camlin Fine Chemicals Limited Previous

CIN History of Camlin Fine Sciences Limited

Camlin Fine Sciences Limited has one previous CIN (Corporate Identification Number): U74100MH1993PLC075361. The current CIN is L74100MH1993PLC075361, which is the unique identifier assigned by the Registrar of Companies.

CIN Status
L74100MH1993PLC075361 Current
U74100MH1993PLC075361 Previous

Associated Brands with Camlin Fine Sciences Limited

Camlin Fine Sciences Limited operates one associated brand: Camlin Fine Sciences. These brands represent Camlin Fine Sciences Limited's diversified market presence and brand portfolio.

Brand Description Website
Camlin Fine Sciences
Manufacturer of fine chemicals catering to food industry camlinfs.com

Business Activity of Camlin Fine Sciences Limited

Camlin Fine Sciences Limited is engaged in the principal business activity of manufacturing, with detailed activities including chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.

Main Activity Group Code Description of Main Activity Business Activity Code Description of Business Activity Turnover Percentage
C Manufacturing C6 Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products Locked
Premium access

Business activity turnover details for Camlin Fine Sciences Limited

Turnover contribution percentages and historical activity changes require an active report plan.

  • Turnover contribution
  • Historical classifications
  • Filing-level activity changes

Verified entity values are shown only after access is granted.

Auditor Details of Camlin Fine Sciences Limited

Camlin Fine Sciences Limited is audited by KALYANIWALLA & MISTRY LLP for the financial year 2024. The auditor plays a crucial role in ensuring financial transparency and compliance with accounting standards.

Name Status Appointment Date Cessation Date
KALYANIWALLA & MISTRY LLP Locked Locked Locked
Premium access

Complete auditor history for Camlin Fine Sciences Limited

Appointment status, appointment dates, cessation dates, and historical auditor changes require an active report plan.

  • Appointment status
  • Appointment dates
  • Cessation dates
  • Auditor changes

Verified entity values are shown only after access is granted.

Board of Directors of Camlin Fine Sciences Limited

Camlin Fine Sciences Limited is currently managed by 12 directors, with 20 former directors having served the organization. The current Directors play a crucial role in shaping the company's strategic direction and governance.

Current Directors
Name Designation Appointment Date Tenure Status
Ashish Subhash Dandekar
Also directs: Mk Falcon Agrotech Private Limited, Abana Medisys Private Limited, Vibha Agencies Private Limited and 2 more
Managing Director 11 Jan 2007 19 Years 8 Months Current
Nirmal Vinod Momaya
Also directs: Mj Medical Devices Private Limited, Abana Medisys Private Limited, Trucap Finance Limited and 5 more
Managing Director 04 Aug 2014 12 Years 1 Months Current
Pradip Manilal Kanakia
Also directs: Healthcare Global Enterprises Limited, Britannia Industries Ltd, Sona Blw Precision Forgings Limited and 5 more
Director 18 Oct 2021 4 Years 11 Months Current
Anagha Subhash Dandekar
Also directs: Camart Finance Limited, Cafco Consultants Limited
Director 28 Aug 2017 9 Years 0 Months Current
Amol Jashvant Shah
Also directs: Anglo Gulf Llp, Organic Biosystems Llp, Fine Aromatics And Herbal Extracts Private Limited and 5 more
Director 02 Aug 2019 7 Years 1 Months Current
Arjun Sudhakar Dukane
Also directs: Chemolutions Chemicals Limited, Naiknavare Chemicals Limited
Whole-Time Director 01 Jun 2018 8 Years 3 Months Current
Showing 6 of 12 current directors. View all directors

Financials of Camlin Fine Sciences Limited FY 2025-26 filings available

Camlin Fine Sciences Limited reported revenue of ₹1,723.31 Cr (up 5.81% YoY) for FY 2025-26.

Financial Highlights

FY 2025-26 · Consolidated
Revenue
₹1,723 Cr
+5.8% YoY
EBITDA
₹91.39 Cr
+1486.8% YoY
Profit After Tax
₹36.46 Cr
+127.8% YoY
Net Worth
₹1,041 Cr
+15.4% YoY
Total Assets
₹1,729 Cr
+12.8% YoY
Total Debt
₹720 Cr
+10.5% YoY

Revenue vs Net Profit ₹ Cr

Margin trends

Financial summary ₹ Cr

MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue1,7231,6291,4541,6821,4121,1871,049
Revenue growth-0.2%+13.4%-2.6%+18.0%+25.4%+9.4%+11.6%
EBITDA91.39(6.59)11.52201158187135
EBITDA margin+5.3%-0.4%+0.8%+12.0%+11.2%+15.7%+12.9%
Profit before tax23.11(159)(99.24)80.3893.9710558.21
Net profit36.46(131)(92.64)56.9460.8350.9530.33
Net profit margin+2.1%-8.1%-6.4%+3.4%+4.3%+4.3%+2.9%
EPS (₹)1.44(7.40)(5.54)3.323.874.002.50
Balance sheet
Total assets1,7291,5331,5461,6301,4361,2661,001
Net worth1,041902865819748643403
Total debt720652683801646550539
Cash & bank15315493.5399.2314213864.79
Net working capital643658602673540585444
Cash flow
Cash from operations82.0723.0013950.9014511786.02
Cash from investing(52.95)(75.35)(66.50)(125)(249)(133)(90.12)
Cash from financing(24.63)76.17(85.97)59.6613638.633.25
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue520425441460408432431417
Revenue growth (YoY)+27.5%-1.6%+2.2%+10.2%+7.1%+14.6%+11.7%+2.8%
Other income2.741112.684.597.5212.971.3411.81
EBITDA(3.66)13.24(6.30)24.1112.7626.9046.88(111)
EBITDA margin-0.7%+3.1%-1.4%+5.2%+3.1%+6.2%+10.9%-26.7%
Depreciation19.1620.8216.3218.8316.1317.1414.4816.51
Interest14.0122.9817.2618.9114.8614.9334.0726.32
Profit before tax(34.09)80.04(37.20)(9.04)(10.71)7.80(0.33)(142)
Tax(0.46)(6.24)(0.09)5.91(0.02)7.697.14(26.20)
Net profit(33.63)86.28(37.11)(14.95)(10.69)0.11(7.47)(116)
EPS (₹)(1.65)4.54(2.38)(0.76)(0.53)(1.24)(0.71)(5.83)
MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue838886773789686600580
Revenue growth-11.6%+21.9%+12.8%+8.5%+13.1%+2.9%+0.9%
EBITDA39.74(16.41)32.7213380.4465.2059.83
EBITDA margin+4.7%-1.9%+4.2%+16.9%+11.7%+10.9%+10.3%
Profit before tax(54.09)(123)(59.64)66.6236.0715.0341.28
Net profit(15.42)18.41(49.07)47.7325.868.5533.10
Net profit margin-1.8%+2.1%-6.4%+6.1%+3.8%+1.4%+5.7%
EPS (₹)(1.72)(4.06)(3.07)3.031.650.652.53
Balance sheet
Total assets1,4181,2961,2321,2641,056846721
Net worth929862716642592465377
Total debt482428511617461378340
Cash & bank80.8984.6513.959.8356.4881.5913.12
Net working capital565558527561441444342
Cash flow
Cash from operations43.9618.1482.1018.5246.8026.0273.90
Cash from investing(30.40)(87.66)(51.72)(115)(172)(88.00)(66.03)
Cash from financing(13.41)105(34.05)78.3912980.05(26.06)
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue222184219244191273205227
Revenue growth (YoY)+16.2%-32.7%+6.8%+7.6%+5.2%+23.7%+10.5%+10.0%
Other income1.4015.305.7710.193.699.206.823.08
Total expenses216180214226187239189309
EBITDA6.823.405.3418.204.6833.2716.39(82.26)
EBITDA margin+3.1%+1.9%+2.4%+7.5%+2.4%+12.2%+8.0%-36.3%
Depreciation13.5113.2913.5113.4713.4013.1313.2613.44
Interest13.3822.0514.8618.7311.3417.4417.1517.92
Profit before tax(18.67)(16.64)(17.26)(3.81)(16.37)11.90(7.20)(111)
Tax(6.36)(10.99)(4.27)(0.17)(5.70)(3.72)(1.57)(37.92)

Financial Statements

Figures in ₹ Cr; negatives in brackets. Updated 26 Sep 2026
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue520425441460408432431417
Revenue growth (YoY)+27.5%-1.6%+2.2%+10.2%+7.1%+14.6%+11.7%+2.8%
Other income2.741112.684.597.5212.971.3411.81
EBITDA(3.66)13.24(6.30)24.1112.7626.9046.88(111)
EBITDA margin-0.7%+3.1%-1.4%+5.2%+3.1%+6.2%+10.9%-26.7%
Depreciation19.1620.8216.3218.8316.1317.1414.4816.51
Interest14.0122.9817.2618.9114.8614.9334.0726.32
Profit before tax(34.09)80.04(37.20)(9.04)(10.71)7.80(0.33)(142)
Tax(0.46)(6.24)(0.09)5.91(0.02)7.697.14(26.20)
Net profit(33.63)86.28(37.11)(14.95)(10.69)0.11(7.47)(116)
EPS (₹)(1.65)4.54(2.38)(0.76)(0.53)(1.24)(0.71)(5.83)
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue1,7231,6291,4541,6821,4121,1871,049
Revenue growth-0.2%+13.4%-2.6%+18.0%+25.4%+9.4%+11.6%
Other income85.5315.6015.555.8033.034.983.43
Total expenses1,6321,6351,4421,4801,2541,000914
Employee cost24418515316314512099.71
EBITDA91.39(6.59)11.52201158187135
EBITDA margin+5.3%-0.4%+0.8%+12.0%+11.2%+15.7%+12.9%
Depreciation70.9260.9656.3562.5155.9644.2932.80
Interest82.8910769.9664.1840.8042.4847.63
Profit before tax23.11(159)(99.24)80.3893.9710558.21
Tax(0.46)(0.51)5.6340.5733.6039.7428.37
Net profit36.46(131)(92.64)56.9460.8350.9530.33
Net profit margin+2.1%-8.1%-6.4%+3.4%+4.3%+4.3%+2.9%
EPS (₹)1.44(7.40)(5.54)3.323.874.002.50
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital19.2118.7916.7515.7115.7012.7512.13
Reserves & surplus1,018880845800729582388
Shareholders' funds (net worth)1,041902865819748643403
Minority interest(40.07)(26.89)(7.80)4.7117.1269.7556.97
Secured loans624529520613411283326
Unsecured loans96.00122163188235267213
Total debt720652683801646550539
Total liabilities1,7291,5331,5461,6301,4361,2661,001
Assets
Gross block1,3271,2711,1691,124816753430
Net block887704816858601584306
Capital work in progress32.859.7345.8743.0221523.82179
Investments30.2660.987.887.967.237.367.36
Inventories504527540568371320298
Sundry debtors373328285305300271253
Cash & bank balances15315493.5399.2314213864.79
Loans & advances20413610911680.8765.6559.21
Total current assets1,2341,1451,0281,088894795675
Total current liabilities591488426415354209230
Net working capital643658602673540585444
Total assets1,7291,5331,5461,6301,4361,2661,001
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash10480.2593.7410875.5252.3753.21
Net cash from operating activities82.0723.0013950.9014511786.02
Net cash from investing activities(52.95)(75.35)(66.50)(125)(249)(133)(90.12)
Net cash from financing activities(24.63)76.17(85.97)59.6613638.633.25
Net change in cash4.4823.82(13.49)(14.07)32.2923.15(0.85)
Closing cash15315493.5399.2314213864.79
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth+5.8%+12.0%-13.5%+19.1%+19.0%+13.2%+17.6%
EBITDA growth+9998.0%--94.3%+27.6%-15.6%+38.2%+85.6%
PBT growth+9998.0%-59.8%--14.5%-10.6%+80.6%+248.6%
Net income growth+9998.0%-41.7%--6.4%+19.4%+68.0%+5129.3%
Revenue CAGR (3Y)+0.8%+4.9%+7.0%+17.0%+16.5%+18.1%+25.3%
EBITDA CAGR (3Y)-23.1%--60.5%+14.2%+29.4%+126.9%+61.9%
Profitability & leverage
Net income margin+1.4%-9.7%-7.2%+2.4%+4.3%+5.5%+2.8%
Return on capital employed+4.7%+11.9%+8.4%+10.7%+11.1%+14.5%+11.9%
Return on net worth+3.3%-17.5%-13.3%+6.3%+10.0%+13.8%+7.7%
Debt / equity0.710.780.941.020.991.151.29
Long-term debt / equity0.320.370.490.580.570.530.54
Interest cover404.93-157.93-156.0646.2540.1029.7946.51
Efficiency & per share
Fixed asset turnover1.331.361.331.872.042.192.66
Inventory turnover3.343.052.623.584.093.843.60
Debtors turnover4.925.314.935.574.954.544.54
EPS (₹)1.44(7.40)(5.54)3.323.874.002.50
Dividend per share (₹)0.000.000.000.000.000.000.00
Book value per share (₹)54.0147.8148.7647.8842.1738.7532.97
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue222184219244191273205227
Revenue growth (YoY)+16.2%-32.7%+6.8%+7.6%+5.2%+23.7%+10.5%+10.0%
Other income1.4015.305.7710.193.699.206.823.08
Total expenses216180214226187239189309
EBITDA6.823.405.3418.204.6833.2716.39(82.26)
EBITDA margin+3.1%+1.9%+2.4%+7.5%+2.4%+12.2%+8.0%-36.3%
Depreciation13.5113.2913.5113.4713.4013.1313.2613.44
Interest13.3822.0514.8618.7311.3417.4417.1517.92
Profit before tax(18.67)(16.64)(17.26)(3.81)(16.37)11.90(7.20)(111)
Tax(6.36)(10.99)(4.27)(0.17)(5.70)(3.72)(1.57)(37.92)
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue838886773789686600580
Revenue growth-11.6%+21.9%+12.8%+8.5%+13.1%+2.9%+0.9%
Other income35.0320.6218.8828.8318.705.4724.06
Total expenses798903741656605535520
Employee cost75.9872.4866.2860.1953.3238.8728.18
EBITDA39.74(16.41)32.7213380.4465.2059.83
EBITDA margin+4.7%-1.9%+4.2%+16.9%+11.7%+10.9%+10.3%
Depreciation53.6852.5349.3932.8226.6819.2811.28
Interest75.1875.1261.8562.3936.3936.3631.33
Profit before tax(54.09)(123)(59.64)66.6236.0715.0341.28
Tax(21.13)(47.12)(8.24)19.0710.216.7410.56
Net profit(15.42)18.41(49.07)47.7325.868.5533.10
Net profit margin-1.8%+2.1%-6.4%+6.1%+3.8%+1.4%+5.7%
EPS (₹)(1.72)(4.06)(3.07)3.031.650.652.53
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital19.2118.7916.7515.7115.7012.7512.13
Reserves & surplus906840696623573403361
Shareholders' funds (net worth)929862716642592465377
Secured loans442412458535328261223
Unsecured loans39.8315.8652.9882.07132117117
Total debt482428511617461378340
Total liabilities1,4181,2961,2321,2641,056846721
Assets
Gross block756755717682381347134
Net block52656957758330429495.64
Capital work in progress22.709.1031.4428.3620718.44198
Investments21710279.8781.8081.7873.5674.02
Inventories24426325525214213197.22
Sundry debtors474414492526441368323
Cash & bank balances80.8984.6513.959.8356.4881.5913.12
Loans & advances12112999.8287.6280.9276.8177.35
Total current assets919891860876721658511
Total current liabilities354333333315279214169
Net working capital565558527561441444342
Total assets1,4181,2961,2321,2641,056846721
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash36.070.684.3522.1718.780.7018.89
Net cash from operating activities43.9618.1482.1018.5246.8026.0273.90
Net cash from investing activities(30.40)(87.66)(51.72)(115)(172)(88.00)(66.03)
Net cash from financing activities(13.41)105(34.05)78.3912980.05(26.06)
Net change in cash0.1535.39(3.67)(17.82)3.3918.08(18.19)
Closing cash80.8984.6513.959.8356.4881.5913.12
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth-5.5%+14.6%-2.1%+15.2%+14.2%+3.5%+5.8%
EBITDA growth+9998.0%--75.4%+65.3%+23.4%+9.0%+81.9%
PBT growth+56.2%-107.0%-+84.7%+140.0%-63.6%+190.9%
Net income growth-+9998.0%-+84.6%+202.5%-74.2%+208.2%
Revenue CAGR (3Y)+2.0%+9.0%+8.8%+10.8%+7.7%+14.2%+21.3%
EBITDA CAGR (3Y)-33.2%--20.5%+30.5%+34.7%+103.0%+34.8%
Profitability & leverage
Net income margin-3.9%-8.6%-6.7%+6.0%+3.8%+1.4%+5.3%
Return on capital employed+2.9%+3.8%+0.2%+11.1%+7.6%+6.6%+10.5%
Return on net worth-1.7%+2.3%-7.6%+7.7%+4.9%+2.0%+8.5%
Debt / equity0.510.600.830.870.790.850.90
Long-term debt / equity0.220.270.400.460.410.340.32
Interest cover-539.31-108.96-371.0362.2867.6979.1864.53
Efficiency & per share
Fixed asset turnover1.111.201.111.491.882.494.73
Inventory turnover3.313.423.054.005.015.255.61
Debtors turnover1.891.961.521.631.701.741.98
EPS (₹)(1.72)(4.06)(3.07)3.031.650.652.53
Dividend per share (₹)0.000.000.000.000.000.000.00
Book value per share (₹)48.1845.7142.5440.6737.5232.5930.80
Want more history and ratios?
You're viewing the latest exchange-filed financials for Camlin Fine Sciences Limited. The full report adds 10+ years of line-item history, 20+ ratios, peer benchmarks and a downloadable PDF.
10+ years of history 20+ ratios & benchmarks Downloadable PDF

Shareholding Pattern of Camlin Fine Sciences Limited

As per the shareholding pattern for the quarter ended Jun 2026, promoters hold 48.00%, foreign institutional investors hold 0.90%, domestic institutional investors hold 5.40%, retail and other public shareholders hold 45.70% of Camlin Fine Sciences Limited.

Promoters: 48.00%DII (Domestic Institutional): 5.40%FII (Foreign Institutional): 0.90%Retail & Others: 45.70%
Jun 2026
QUARTER
48.00% Promoters
5.40% DII (Domestic Institutional)
0.90% FII (Foreign Institutional)
45.70% Retail & Others
Promoter holding - history
Now 48.00% · Jun 2026High 49.10% · Sep 2025Low 48.00% · Dec 2025
47%48%49%50%51%Sep 2025Dec 2025Mar 2026Jun 2026Sep 2025: 49.10%Dec 2025: 48.00%Mar 2026: 48.00%Jun 2026: 48.00%49.10%48.00%48.00%
Shareholding trend - last 6 quarters
Jun 2026Mar 2026Dec 2025Sep 2025
Promoters48.00%48.00%48.00%49.10%
Public52.00%52.00%52.00%50.90%

Group Structure of Camlin Fine Sciences Limited

Camlin Fine Sciences Limited has 2 subsidiary companies. This group structure data is as of FY 2023. The corporate group structure reflects Camlin Fine Sciences Limited's business expansion strategy and organizational complexity.

2
Subsidiary companies
Key Subsidiaries
Company Name CIN Shares Held
Chemolutions Chemicals Ltd. U24100MH2008PLC180376 -
Algalr Nutrapharms Private Limited U74900TN2014PTC096649 -

Showing major subsidiaries. Total: 2.

Charges & Borrowings of Camlin Fine Sciences Limited

Open charges
₹636.6 Cr
Satisfied charges
₹1,187.59 Cr
Breakdown by lending institutions
Sbicap Trustee Company Limited₹429.00 Cr
Idbi Trusteeship Services Limited₹110.00 Cr
Others₹96.82 Cr
Hdfc Bank Limited₹0.78 Cr
Latest charge details
DateLenderAmountStatus
14 Nov 2025 Others ₹17 Lakh Open
27 Jun 2023 Hdfc Bank Limited ₹44 Lakh Open
01 Sep 2022 Others ₹1.65 Cr Open
21 Jul 2022 Others ₹95 Cr Open
20 May 2022 Hdfc Bank Limited ₹34.3 Lakh Open

Total charge records: 37 View all charges

Employees and EPFO Compliance at Camlin Fine Sciences Limited

Camlin Fine Sciences Limited has a workforce of 612 employees as of Apr 09, 2024.

Employee count
612
Active EPFO establishments
2
Employee growth
6.62%
Premium access

Employee and EPFO history for Camlin Fine Sciences Limited

Monthly headcount, contribution history, establishment records, and filing compliance require an active report plan.

  • Monthly headcount
  • PF contributions
  • ECR filing status
  • Establishment history

Verified entity values are shown only after access is granted.

GST Compliance of Camlin Fine Sciences Limited

Premium access

GST registrations and filing compliance for Camlin Fine Sciences Limited

State-wise registrations, return filing status, HSN and SAC details, and jurisdiction records require an active report plan.

  • GSTIN registrations
  • State-wise filing status
  • HSN and SAC details
  • Tax jurisdiction records

Verified entity values are shown only after access is granted.

Credit Ratings, Litigation & Regulatory Alerts for Camlin Fine Sciences Limited

Premium access

Credit ratings, litigation, and regulatory alerts for Camlin Fine Sciences Limited

Agency ratings, court records, regulatory events, and entity-specific compliance alerts require an active report plan.

  • Rating history
  • Court and tribunal cases
  • Regulatory alerts
  • Director-linked violations

Verified entity values are shown only after access is granted.

MSME Payment Delays by Camlin Fine Sciences Limited

Premium access

MSME payment history for Camlin Fine Sciences Limited

Amounts outstanding to micro and small suppliers, delay reasons, and MSME-1 filing history require an active report plan.

  • Outstanding amounts
  • Delay periods and reasons
  • MSME-1 filing history
  • Vendor payment signals

Verified entity values are shown only after access is granted.

Subsidiaries & Group Companies of Camlin Fine Sciences Limited

Premium access

Corporate group structure for Camlin Fine Sciences Limited

Parent, subsidiary, associate, joint venture, and ownership records require an active report plan.

  • Parent company
  • Subsidiaries and ownership
  • Associates and joint ventures
  • Entity investments

Verified entity values are shown only after access is granted.

MCA Filings & Documents of Camlin Fine Sciences Limited

Premium access

MCA filings and documents for Camlin Fine Sciences Limited

Official forms, annual returns, financial statements, charge filings, and document dates require an active report plan.

  • Incorporation documents
  • Annual returns and statements
  • Charge filings
  • Complete filing index

Verified entity values are shown only after access is granted.

Recent Activity on Camlin Fine Sciences Limited

Charges
28 Apr 2026
A charge with Sbicap Trustee Company Limited of Rs. 429.00 Cr registered on 29 Jun 2020 with Charge ID 100352495 was modified on 28 Apr 2026.
Charges
16 Dec 2025
A charge with Others of Rs. 0.17 Cr registered on 14 Nov 2025 with Charge ID 101196871 was modified on 16 Dec 2025.
Charges
14 Nov 2025
A charge with Others amounted to Rs. 0.17 Cr with Charge ID 101196871 was registered on 14 Nov 2025.
Activity
08 Aug 2025
Camlin Fine Sciences Limited last Annual general meeting of members was held on 08 Aug 2025 as per latest MCA records.
Activity
31 Mar 2025
Camlin Fine Sciences Limited has filed its annual Financial statements for the year ended 31 Mar 2025 with Roc Mumbai I.
Directors
12 Mar 2025
Radhika Madhukar Dudhat was appointed as a Director on 12 Mar 2025 & has been associated with this company since 1 year 6 months.

Recent News on Camlin Fine Sciences Limited

Frequently Asked Questions about Camlin Fine Sciences Limited

Camlin Fine Sciences Limited is an active public limited company in the chemicals and materials sector based in Mumbai, Maharashtra, India. It was incorporated on 30 November 1993 (33+ years old) and is registered under CIN L74100MH1993PLC075361. Listed on BSE: 532834 and NSE: CAMLINFINE. The company has 612 employees.

Camlin Fine Sciences Limited reported revenue of ₹1,723.31 Cr for FY 2025-26 (up 5.81% YoY) based on consolidated financials.

The current directors of Camlin Fine Sciences Limited are:

The primary industry of Camlin Fine Sciences Limited is chemicals and materials. The company specifically operates in specialty chemicals. The company is currently active in this sector.

Yes. Camlin Fine Sciences Limited is listed on both BSE (code: 532834) and NSE (symbol: CAMLINFINE).

Camlin Fine Sciences Limited can be reached at the registered office: In G.S. Point Plot No. Viii C.S.T. Road Private Layout Scheme Kalina Santacruz, East, Mumbai, Maharashtra, India – 400098, or through the website camlinfs.com.

7M+ Indian companies. One platform.

Financials, directors, compliance, charges and shareholding - compiled from official filings and updated regularly.

Subscription plans available